<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Key Discoveries in the Development of Modern HUB Organoids

Key discoveries in the development of modern HUB Organoids

Key discoveries in the development of modern HUB OrganoidsLearn about the key research discoveries leading to the development of modern HUB Organoids.

Milestone Discoveries in the Development of HUB Organoids

Today’s modern adult stem cell-derived HUB Organoids are the outcome of a massive research effort, spanning decades and encompassing a series of historical research milestone discoveries in stem cell culturing.

Early Milestone Discovery: Stem Cell Cultures for Developmental Biology Studies

The first ex vivo stem cell expansion studies focused on establishing long-term stem cell cultures to model human development. These efforts date back to the late 1970s and early 80s, when adult keratinocytes or embryonic pluripotent cells were co-cultured with a layer of fibroblast feeder cells. These provided a cellular source of undefined stem cell niche factors, though this was unknown at the time.

Despite these efforts, stem cells grown in the presence of feeder cells quickly became genetically unstable and lost their full differentiation potential. This means that in vitro differentiation could be somewhat limited and unpredictable. As a precautionary step, cultured (putative) stem cells were transplanted into mice to see whether they still possessed stem cell defining characteristics of: 1) the capacity to self-renew and 2) differentiation into multiple lineages.

Subsequent Milestone Discoveries: Enhanced Understanding of the Stem Cell Niche and the Regulation of Stem Cell Self-Renewal and Differentiation

Two subsequent discoveries resulted in optimized protocols for establishing organoids from human multipotent organ-specific adult stem cells (ASCs), now known as “HUB Organoids”.

The first milestone published by the Clevers lab, was the discovery of Lgr5 as a biomarker to identify adult intestinal stem cells. This discovery allowed the characterization, purification, and in vitro expansion of the first ASCs.

The observation that these ASCs proliferate and can be maintained in long term culture led to using isolated Lgr5+ stem cells as a putative cellular source for organoid cultures. This seminal work resulted in developing the first gut “mini-organs” (specifically, crypt-villus organoids).

The second major discovery was an enhanced understanding of the stem cell niche, and of the factors that regulate stem cell self-renewal and differentiation. This key aspect meant that feeder cells were no longer required. Instead, the stem cell culture environment is simply supplemented with organ-specific cocktails of growth factors.

The Clevers research group shattered the common dogma by showing that self-organizing near-native intestinal epithelial structures could be generated from single stem cells in the absence of a mesenchymal cellular niche.

Modern HUB Organoid Culture

Modern HUB Organoid culture is based on refined protocols optimized by the Clevers lab and HUB. This includes the optimization of organoid culture medium over a number of years. The refined media allows the generation of organoid cultures from epithelial ASCs in the absence of a mesenchymal cellular niche, and includes

  • Stem cell niche factors: epidermal growth factor (EGF), Noggin, and R-spondins following discoveries showing that

  • A rho kinase (ROCK) inhibitor following work showing that adding it to primary cultures successfully inhibited anoikis (a form of cell death that occurs in anchorage-dependent cells) previously observed in purified colonic epithelial cells.

  • Finally, embedding purified ASCs in Matrigel provided a key ex vivo substitute for the extracellular matrix (ECM). This was selected after previous experiences with feeder layer cultures showed that feeder cells (i.e. fibroblasts) produce ECM to support stem cell growth. Preincubation of the tissue culture plastic with ECM proteins (such as collagen or laminin) further enhanced stem cell clonogenicity. Also, ECM-based hydrogels, such as Matrigel®, could foster 3D aggregation and polarization of (stem) cells.

Using these approaches modern HUB Organoids are now derived from range of epithelial tissues.

Modern HUB Organoid Discoveries - What's Next?

Recent discoveries are allowing organoid cultures to become useful in assessing immunotherapies.

While HUB Organoids do faithfully recapitulate human epithelial organ morphogenesis and pathogenesis, they lack the communication between organs found in complex in vivo organisms. Specifically, for a disease such as cancer, co-operation between the tumor itself and the immune system is crucial for disease establishment and progression. Both cancer and immune cells are therefore needed to effectively evaluate immunotherapies.

New studies show that tumor organoids can be co-cultured with autologous activated T cells. Co-cultures of autologous tumor organoids and peripheral blood lymphocytes were used to enrich tumor-reactive T cells from the peripheral blood of patients with mismatch repair-deficient colorectal cancer and non-small-cell lung cancer. These T cells were then used to assess the efficiency of killing matched tumor organoids.

Conclusion

Modern organoid cultures are the result of several historical research discoveries, including early studies showing stem cells could be cultured in vitro, followed by later studies that improved our understanding of the stem cell niche and the regulation of stem cell self-renewal and differentiation.

Today, optimized HUB Organoid protocols are widely used to generate robust and reproducible organoid cultures that can be maintained long-term in vitro.


Related Posts